<DOC>
	<DOCNO>NCT00273364</DOCNO>
	<brief_summary>Multiple sclerosis ( MS ) onset immune-mediated demyelinating disease . In case , start relapsing-remitting disease distinct attack symptom flare . Over year decade , virtually case transition progressive disease insidious slow neurologic deterioration occur without acute flare . Relapsing-remitting disease often responsive immune suppressive modulating therapy , immune base therapy generally ineffective patient progressive clinical course . This clinical course response immune suppression , well neuropathology neuroimaging study , suggest disease progression associate axonal atrophy . Disability correlate good measure axonal atrophy immune mediate demyelination . Therefore , immune base therapy , order effective , need start early disease course MS predominately immune-mediated inflammatory disease . While current immune base therapy delay disability , intervention proven prevent progressive disability . We propose , randomize study , autologous unmanipulated PBSCT use condition regimen cyclophosphamide rATG versus FDA approve standard care ( i.e . interferon , glatiramer acetate , mitoxantrone , natalizumab , fingolimod , tecfidera ) patient inflammatory ( relapse ) MS despite treatment alternate approve therapy .</brief_summary>
	<brief_title>Stem Cell Therapy Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study</brief_title>
	<detailed_description>To assess efficacy autologous PBSCT versus FDA approve standard care ( i.e . interferon , glatiramer acetate , mitoxantrone , natalizumab , fingolimod , tecfidera ) inflammatory multiple sclerosis ( MS ) fail fail alternate approve therapy . The endpoint consider study : 2.1 Primary Endpoint : Disease progression , define 1 point increase Expanded Disability Status Scale ( EDSS ) consecutive evaluation least 6 month apart due non-MS disease process . Patients follow 5 year randomization . 2.2 Secondary Endpoints : 1 . Number relapse , define acute neurologic deterioration occur engraftment last 24 hour , accompany objective worsen neurological examination document blinded neurologist explain fever , infection , stress heat relate pseudo-exacerbation . Supportive confirmation enhancement MRI prefer mandatory . 2 . Ambulation index 3 . Twenty-five foot time walk 4 . Nine hole PEG test 5 . PASAT- 3 second PASAT - 2 second 6 . MSFC 7 . MRI enhance lesion T1 T2 burden disease per MRI-AC MRI protocol 8 . SF-36 9 . Scripps NRS 10 . Survival</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>1 . Age between1855 , inclusive . 2 . Diagnosis MS use revise McDonald criterion clinically definite MS ( Appendix I ) . 3 . An EDSS score 2.0 6.0 ( Appendix II ) . 4 . Inflammatory disease despite treatment standard disease modify therapy include least 6 month interferon copaxone . Inflammatory disease define base MRI ( gadolinium enhance lesion ) clinical activity ( acute relapse *treated IV oral high dose corticosteroid prescribe neurologist ) . Minimum disease activity require failure define : ) two *steroid treat clinical relapse document new objective sign neurological examination document neurologist within year prior study , b ) one *steroid treat clinical relapse within year prior study evidence MRI active inflammation ( i.e. , gadolinium enhancement ) within last 12 month occasion separate clinical relapse ( 3 month clinical relapse ) . A steroid treat relapse include relapse severe enough justify treatment due patient intolerance steroid , history nonresponse steroid , offer use . Exclusion Criteria** 1 . Any illness opinion investigator would jeopardize ability patient tolerate aggressive chemotherapy . 2 . Prior history malignancy except localize basal cell , squamous skin cancer carcinoma situ cervix . Other malignancy patient judge cure , head neck cancer , breast cancer consider individual basis . 3 . Positive pregnancy test 4 . Inability unwillingness pursue effective mean birth control time evaluation eligibility 6 month posttransplant ( transplant ) appropriate nontransplant treatment ( control arm ) . Effective birth control define 1 ) abstinence define refrain act vaginal intercourse ; 2 ) consistent use birth control pills ; 3 ) injectable birth control method ( Depoprovera , Norplant ) ; 4 ) tubal sterilization male partner undergone vasectomy ; 5 ) placement intrauterine device ( IUD ) ; 6 ) use , every act intercourse , diaphragm contraceptive jelly and/or condom contraceptive foam . 5 . Failure willingly accept comprehend irreversible sterility side effect therapy 6 . FEV1/FVC &lt; 60 % predict bronchodilator therapy ( necessary ) 7 . DLCO &lt; 50 % predict ( transplant arm ) 8 . Resting LVEF &lt; 50 % 9 . Bilirubin &gt; 2.0 mg/dl 10 . Serum creatinine &gt; 2.0 mg/dl 11 . Known hypersensitivity mouse , rabbit , E. Coli derive protein , iron compounds/medications 12 . Presence metallic object implant body would preclude ability patient safely MRI exams 13 . Diagnosis primary progressive MS 14 . Diagnosis secondary progressive MS 15 . Platelet count &lt; 100,000/ul , WBC &lt; 1,500 cells/mm3 16 . Psychiatric illness , mental deficiency cognitive dysfunction make compliance treatment inform consent impossible 17 . Active infection except asymptomatic bacteriuria 18 . Use natalizumab ( Tysabri ) within previous 6 month 19 . Use fingolimod ( Gilenya ) within previous 3 month 20 . Use Teriflunomide ( Aubagio ) within previous 2 year unless clear body ( plasma concentration &lt; 0.02mcg/ml ) follow elimination body cholestyramine 8g three time day 11 day 21 . Prior treatment CAMPATH ( alemtuzumab ) 22 . Prior treatment mitoxantrone 23 . Any hereditary neurological disease CharcotMarieTooth disease ( CMT ) Spinocerebellar ataxia ( SCA ) contraindication 24 . Use tecfidera within previous 3 month For patient clearly inflammatory disease , exception make agree upon study PI least two study neurologist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stem cell , autoimmune disease , multiple sclerosis</keyword>
</DOC>